We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $492.69, indicating a -1.96% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily ...

We recently published a list of Jim Cramer Looked At These 23 Stocks Recently. In this article, we are going to take a look ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.60% to $484.82 Monday, on what proved to be an all-around favorable ...

Vertex Pharmaceuticals saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The company ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Vertex Pharmaceuticals has a 1 year low of $377.85 and a 1 year high of $519.88. The stock’s 50 day simple moving average is $464.06 and its 200-day simple moving average is $462.31.

Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of ...